Osthol

Category	Hepatitis B Virus (HBV)
CAS	484-12-8
Description	Osthole is a coumarin which is isolated from Cnidium monnieri (L.) Cusson. Osthole is a calcium channel modulator via inhibiting phosphodiesterases. It also regulates the expression of TNF-α, NF-κB, TGF-β, cyclooxygenases, leukotrienes, nitric oxide, ERK, and JNK. Osthole is a natural compound used in cosmetics material.

Quotation Now

Product Information

Synonyms	Osthol; 7-methoxy-8-(3-methylbut-2-en-1-yl)-2H-chromen-2-one
IUPAC Name	7-methoxy-8-(3-methylbut-2-enyl)chromen-2-one
Molecular Weight	244.29
Molecular Formula	C15H16O3
Canonical SMILES	CC(=CCC1=C(C=CC2=C1OC(=O)C=C2)OC)C
InChI	InChI=1S/C15H16O3/c1-10(2)4-7-12-13(17-3)8-5-11-6-9-14(16)18-15(11)12/h4-6,8-9H,7H2,1-3H3
InChIKey	MBRLOUHOWLUMFF-UHFFFAOYSA-N
Boiling Point	396.7±42.0 °C at 760 mmHg
Melting Point	83-84°C
Flash Point	167.6±22.5 °C
Purity	≥ 98%
Density	1.126 g/cm3
Solubility	In vitro: 10 mM in DMSO
Appearance	Cryst.
Application	anti-tumor; anti-cancer; may be used as bio-pesticides
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	366
Exact Mass	244.109944368
Index Of Refraction	1.557
In Vitro	Osthole (p<0.0001) and Fexofenadine (p<0.001) inhibit increased HRH-1 mRNA expression induced by histamine in the study group. This result is also observed in cells cultured with histamine/Osthole; where combined substances decreased HRH-1 mRNA expression compared to histamine (p<0.0001). Assessment of cell viability does not detect obvious toxicity when Osthole is used at a dose up to 100 µM. However, when the dose reached 500 µM, Osthole started to show toxic effect. Based on these observations, Osthole is used in all in vitro studies at the dose range of 10 to 100 µM. Osthole dose-dependently promotes osteoblast differentiation, as shown by the upregulation of osteoblast differentiation marker genes such as type I collagen (col1), bone sialoprotein (BSP) and osteocalcin (OC) (2 days of culture). Osthole promotes ALP activity in mouse primary osteoblasts in a dose-dependent manner.
In Vivo	Subcutaneous injection of Osthole at a dose of 5 mg/kg per day onto mouse calvariae significantly stimulates local bone formation, as shown by histologic analysis of calvarial samples harvested 2 weeks after the last injection and stained with H&E orange G. Histomorphometric analysis reveals that Osthole has a significant effect on bone formation as potent as the positive control, the microtubule inhibitor TN-16. This effect, however, is not seen when Osthole is used at a dose of 1 mg/kg per day. Intraperitoneal injection of Osthole for 8 weeks significantly reverses bone loss in the ovariectomized rats. Histologic examination of the L4samples stained with trinitrophenol poinsettia demonstrates a partial recovery of the trabecular structure in ovariectomized rats treated with Osthole. Histomorphometric analysis shows that treatment with Osthole significantly increases total BMD, trabecular bone volume, and trabecular thickness and decreases trabecular separation.
PSA	39.44000
Target	Histamine Receptor; Apoptosis; Parasite; HBV
Vapor Pressure	0.0±0.9 mmHg at 25°C
XLogP3-AA	3.8